[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2012 Global CA Tumor Markers Diagnostics Market Outlook: Test Volumes, Sales Forecasts, and Supplier Shares by Country

April 2012 | 278 pages | ID: C236E1DB48EEN
Venture Planning Group

US$ 3,880.00 US$ 4,850.00 -20 %

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

This report presents a detailed analysis of the CA 15-3/27.29, CA 19-9, and CA 125 testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers.

The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.

Contains 278 pages and 40 tables
I. INTRODUCTION

II. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW


A. CA Tumor Markers: Clinical Significance and Laboratory Practices
  1. CA 15-3/27.29
  2. CA 19-9
  3. CA 125
B. Instrumentation Review And Market Needs
  1. Abbott AxSYM
  2. Abbott IMx
  3. Anagen AN2000/AuraFlex
  4. Beckman Coulter Access
  5. BioChem Pharma SR1
  6. bioMerieux Vidas Series
  7. Biotrol Systems 7000
  8. J&J Diagnostics/Amersham Amerlite
  9. J&J Diagnostics Vitros ECI
  10. Olympus PK Series
  11. Roche Cobas Core
  12. Roche Elecsys
  13. Roche ES 22
  14. Roche ES 33
  15. Roche ES 300/300 AL
  16. Siemens ACS: 180
  17. Siemens ACS: Centaur
  18. Siemens ELISA Processor II/III
  19. Siemens Immuno 1
  20. Siemens/Opus/Plus/Magnum
  21. Siemens Stratus
  22. Tosoh AIA Series
  23. Wallac/Pharmacia Delfia
C. Current and Emerging Technologies
  1. Monoclonal and Polyclonal Antibodies
  2. Immunoassays
    a. Technological Principle
    b. Radioimmunoassay (RIA)
    c. Enzyme Immunoassays (EIA)
      Overview
      ELISA
      Immunofiltration
      Particle-Membrane Capture Immunoassay
      Enzyme Amplification
    d. Fluorescent Immunoassays
    e. Luminescence
      Chemiluminescence
      Bioluminescence
  3. Molecular Diagnostics
    a. Technology Overview
    b. Amplification Methods
      PCR
      DAP-PCR
      Immuno-PCR
      QC-PCR
      CAR
      DNA
      HPA
      LCR
      NASBA
      QBR
      SDA
      3 SR, and others
  4. Biochips/Microarrays
  5. Chromosome Analysis
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
  6. Microcomputers and Automation
  7. Artificial Intelligence
  8. Flow Cytometry
  9. Biosensors
D. Competing/Complementing Technologies
  1. CT
  2. MRI
  3. NMR
  4. PET
  5.Photonics Spectroscopy
E. Personal Testing

III. FRANCE: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

IV. GERMANY: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

V. ITALY: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT

VI. JAPAN: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

VII. SPAIN: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

VIII. U.K.: TEST VOLUME AND DIAGNOSTICS SALES FORECAST BY MARKET SEGMENT

IX. U.S.A.: MARKET SIZE, GROWTH AND MAJOR SUPPLIERS’ SALES AND MARKET SHARES

X. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

XI. ALTERNATIVE MARKET PENETRATION STRATEGIES


A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
  1. Marketing Approaches
  2. Product Complexity
  3. Customer Preference
  4. Established Suppliers
  5. Emerging Suppliers
  6. Major Types of Distributors
  7. Market Segmentation Factor

XII. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

XIII. COMPETITIVE PROFILES

Abbott
AdnaGen
Ambrilia Biopharma
AMDL
Beckman Coulter
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CanAG Diagnostics
CeMines
Cepheid
Correlogic Systems
Dako
Decode
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Enterix
Enzo Biochem
Epigenomics
Exact Sciences
Fujirebio
Gen-Probe
Guided Therapeutics
Hologic
Ipsogen
J&J Diagnostics
Kreatech
Kyowa Medex
Mackay Life Sciences
Matritech
Myriad Genetics
OncoLab
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Veridex
Wako Pure Chemicals
Wallac
Zila

LIST OF TABLES

Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
France CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
France CA 19-9 Test Volume and Diagnostics Sales by Market Segment
France CA 125 Test Volume and Diagnostics Sales by Market Segment
France CA 15-3/27.29 Testing Market by Major Supplier
France CA 19-9 Testing Market by Major Supplier
France CA 125 Testing Market by Major Supplier
Germany CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
Germany CA 19-9 Test Volume and Diagnostics Sales by Market Segment
Germany CA 125 Test Volume and Diagnostics Sales by Market Segment
Germany CA 15-3/27.29 Testing Market by Major Supplier
Germany CA 19-9 Testing Market by Major Supplier
Germany CA 125 Testing Market by Major Supplier
Italy CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
Italy CA 19-9 Test Volume and Diagnostics Sales by Market Segment
Italy CA 125 Test Volume and Diagnostics Sales by Market Segment
Japan CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
Japan CA 19-9 Test Volume and Diagnostics Sales by Market Segment
Japan CA 125 Test Volume and Diagnostics Sales by Market Segment
Japan CA 15-3/27.29 Testing Market by Major Supplier
Japan CA 19-9 Testing Market by Major Supplier
Japan CA 125 Testing Market by Major Supplier
Spain CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
Spain CA 19-9 Test Volume and Diagnostics Sales by Market Segment
Spain CA 125 Test Volume and Diagnostics Sales by Market Segment
Spain CA 15-3/27.29 Testing Market by Major Supplier
Spain CA 19-9 Testing Market by Major Supplier
Spain CA 125 Testing Market by Major Supplier
U.K. CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
U.K. CA 19-9 Test Volume and Diagnostics Sales by Market Segment
U.K. CA 125 Test Volume and Diagnostics Sales by Market Segment
U.S.A. CA 15-3/27.29 Test Volume and Diagnostics Sales by Market Segment
U.S.A. CA 19-9 Test Volume and Diagnostics Sales by Market Segment
U.S.A. CA 125 Test Volume and Diagnostics Sales by Market Segment
U.S.A. CA 15-3/27.29 Testing Market by Major Supplier
U.S.A. CA 19-9 Testing Market by Major Supplier
U.S.A. CA 125 Testing Market by Major Supplier


More Publications